RAP1A AND RAP1B IN THE DIAGNOSIS AND TMT - ORAL CANCER

RAP1A 和 RAP1B 在诊断和 TMT - 口腔癌中的应用

• 批准号: 6702599
• 负责人: Nisha J D'Silva
• 金额: $ 13.07万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6702599
• 关键词: SCID mouse; biomarker; cell cycle; clinical research; epithelium; gene expression; gene mutation; guanine nucleotide binding protein; human tissue; immunocytochemistry; neoplasm /cancer diagnosis; neoplastic transformation; oral pharyngeal neoplasm; prognosis; protein isoforms; squamous cell carcinoma; tumor suppressor genes; western blottings

Candidate: The candidate has been involved in clinically relevant basic science research during the post-doctoral studies. This training and the candidate's understanding of confounding clinico-pathologic issues have contributed to her commitment to pursue translational research in oral cancer. The immediate goal is internationally renowned clinician- scientists. The long-term goal is to become an independent translational scientist capable of bridging the gap between the laboratory bench and patient care. Environment: The University of Michigan is a nurturing environment for the clinician-scientist. The Cancer Center is internationally reputed for its pioneering work in clinical and biomedical research. The developments in basic science knowledge are translated into improvements in patient care. Research Career Development Plant: The plan encompasses the 5 year award period and includes supervised basic science and translational research rotations, Head and Neck Cancer Symposia, weekly signaling, research responsibility and ethics. Research Project: The overall objective of this proposal is to enhance the understanding of the molecular choices of oral cancer. Rap1, a ras-like protein, will be evaluated as a predictive biomarker for malignant transformation of precancerous human oral epithelial lesions. Additionally, a rap1B, a rap1 isoform, will be assessed as a candidate protein for prognosis prediction, when used as a biomarker for metastatic potential of squamous cell carcinoma (SCC). This would allow the identification of lesions that should be treated more aggressively. The third segment involves the design of a protocol to investigate the use of rap1A in gene therapy to treat residual epithelial dysplasia or squamous cell carcinoma lesions.

候选人：在博士后研究期间参与过临床相关基础科学研究。这种培训和候选人的混淆临床病理问题的理解，有助于她致力于追求口腔癌的转化研究。近期目标是国际知名的临床科学家。长期目标是成为一名独立的翻译科学家，能够弥合实验室工作台和患者护理之间的差距。环境：密歇根大学是一个培养临床科学家的环境。癌症中心因其在临床和生物医学研究方面的开创性工作而享誉国际。基础科学知识的发展转化为病人护理的改善。研究职业发展工厂：该计划包括5年的奖励期，包括监督基础科学和转化研究轮换，头颈癌研讨会，每周信号，研究责任和道德。研究计划：本计划的总体目标是加强对口腔癌分子选择的理解。Rap1是一种ras样蛋白，将被评估为人类口腔上皮癌前病变恶变的预测生物标志物。此外，rap1B，rap1亚型，将被评估为预后预测的候选蛋白，当用作鳞状细胞癌（SCC）转移潜力的生物标志物。这将允许识别应该更积极治疗的病变。第三部分涉及一个协议的设计，调查使用rap1A基因治疗，以治疗残留的上皮异型增生或鳞状细胞癌病变。